Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Subramanyam Santhanam

Nephrology Evanston, IL Medical Doctor

NPI 1225112741 CMS profile 540302

2650 Ridge Ave, Div Of Nephrology, Evanston, IL 60201

Open in the dashboard

General payments

$5,894

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Subramanyam Santhanam of Evanston, IL is reported in the CMS Open Payments database as having received $5,894 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 5
2024 General $552 12
2023 General $679 14
2022 General $1,011 21
2021 General $523 11
2020 General $490 6
2019 General $2,404 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Subramanyam Santhanam
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Subramanyam Santhanam were reported at $234. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Subramanyam Santhanam Nephrology median Middle half National median
2019 $2,404 $236 $90–$588 $163
2020 $490 $135 $46–$364 $114
2021 $523 $202 $67–$551 $132
2022 $1,011 $242 $77–$695 $149
2023 $679 $254 $84–$766 $160
2024 $552 $300 $99–$852 $164
2025 $234 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mallinckrodt Hospital Products Inc. $894 13 payments
  2. AstraZeneca Pharmaceuticals LP $544 8 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $532 6 payments
  4. Alexion Pharmaceuticals, Inc. $435 7 payments
  5. Horizon Therapeutics plc $414 5 payments
  6. Retrophin, Inc. $352 6 payments
  7. Amgen Inc. $340 4 payments
  8. Janssen Pharmaceuticals, Inc $319 4 payments
  9. Radius Health, Inc. $313 3 payments
  10. Novartis Pharmaceuticals Corporation $243 2 payments
  11. Other $1,507 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,874 91 payments
  2. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. ACTHAR $894 13 payments
  2. KRYSTEXXA $414 5 payments
  3. LOKELMA $353 3 payments
  4. Tymlos $313 3 payments
  5. (815) Thiola $263 2 payments
  6. COSENTYX $243 2 payments
  7. TAVNEOS $235 3 payments
  8. INVOKANA $220 3 payments
  9. JYNARQUE $172 8 payments
  10. RAYALDEE $161 3 payments
  11. Other $1,717 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record